Press Release

Kiel and Hamburg, Germany, and Vienna, Austria, 06 March 2020 - LKF - Laboratorium für Klinische Forschung GmbH, a subsidiary of GBA Group Pharma, is honouring International Women's Day on 8 March 2020 by highlighting the company's female success factors.

"Every day is Women's Day at LKF," says Bärbel Wilke, co-founder and CEO of LKF, with 80 percent of its 150 employees being women. Many of the 120 female employees working in the three-storey laboratory are highly qualified specialists and scientists from the fields of chemistry, biology, molecular biology et al.

The “standstill” transition period begins as the Withdrawal Agreement clears the final hurdle.

Three-and-a-half years since the Brexit vote, the UK has left the EU – with a deal. There was no late drama as the European Parliament approved the Withdrawal Agreement by 621 votes to 49.

The UK now enters a “transition period.” Although the UK will have no MEPs, no Commissioner, and no seat at the EU Council; EU law will continue to apply in the UK. And that means companies can continue UK batch release testing and qualified person (QP) certification; marketing authorization (MA) holders and QPs, and QPPVs can continue to be based in the UK and access EU markets; manufacturing and distribution licences will continue to be recognized by the EU and vice versa, as will inspections; and UK-based firms can continue to apply for MAs via either the centralized or decentralized procedure (1) * published in the Medicine Maker on 11th of February 2020

Medikamente. Import, Export und Herstellung von Arzneimittelnin der EU stehen im Fokus von ABF Pharmaceutical Services.

Gerade rechtzeitig zum Brexit hat die 2004 in Wien gegründete ABF Pharmaceutical Services (GBA Group Pharma), der einzige internationale Komplettdienstleister für Import, Export und Herstellung von Medikamenten in klinischen Studien (Prüfware) in Österreich, ihre Kapazitäten am neuen Standort in Wien 23 mehr als verdoppelt. Und das nicht nur aufgrund der wachsenden Nachfrage der internationalen Pharma- und Biotech-Branche, sondern auch um der Rolle eines Brexit Safe Havens gerecht zu werden.

Gastkommentar

Neuer Standort als Brexit Safe Haven 2019 war das Jahr des Wachstums. Die 2004 in Wien gegründete ABF hat aufgrund der stark wachsenden Nachfrage der internationalen Pharma- und Biotech-Branche ihre Kapazitäten am Wiener Standort um das 2,5-Fache erweitert. Grund dafür war auch, der Rolle eines Brexit Safe Havens gerecht zu werden. Der Brexit war 2019 und bleibt weiterhin, ein zentrales Thema für die Pharmaindustrie, da es für die Herstellung von Medikamenten in der EU klare Regularien gibt. Im Falle eines Austritts von Großbritannien aus der EU wäre die ABF mit ihren Partnerfirmen in der GBA Group Pharma einer der wenigen Dienstleister in der EU, die diese Kriterien abdecken können.

Die Presse, 31.12.2019

From September 25th to September 26th the 6th European Forum on Extractables, Leachables, Medial Devices and Contact Materials Testing take place in Hamburg. The forum focuses on industry testing requirements for the identification and characterization of extractable, leachable (E&L), and non-intentionally added substances (NIAS) contaminants. Presentations from leaders in their field takes place over 2 days. On the 2nd day Dr. Heike Schmidt-Eisenlohr, expert for E&L studies at GBA Pharma Labs, presents a speech on ‘Extractable & Leachable Study with Integrity Testing & Toxicological Assessment’.